



ELCC 2017 Industry Satellite Symposium

Choices across treatment lines: Maximising patient outcomes in advanced or metastatic NSCLC

Chaired by Luis Paz-Ares

Saturday 6th May 2017, 13:00-14:00, Room A, Palexpo

 Springer Healthcare IME

This independent programme is made possible thanks to educational sponsorship from Eli Lilly and Company

Contents

- 3 Programme**
- 3 Learning objectives**
- 4 Welcome message**
- 5 Faculty biographies**
Luis Paz-Ares
- 6 Faculty biographies**
Egbert Smit
- 7 Faculty biographies**
Benjamin Besse
- 8 Symposium information**
- 9 Notes**

Programme

13:00 – 13:05	Welcome and introduction	Luis Paz-Ares (Spain)
13:05 – 13:30	Individualising treatment options to improve squamous NSCLC patient outcomes	Egbert Smit (The Netherlands)
13:30 – 13:55	Patient pathways in rapid progression	Benjamin Besse (France)
13:55 – 14:00	Closing remarks	Luis Paz-Ares

Learning objectives

Following attendance at this symposium delegates should be able to:

- Explain the remaining high unmet therapeutic needs for patients with advanced squamous NSCLC in comparison to those with adenocarcinoma.
- Describe the optimal treatment path for advanced non-squamous NSCLC patients who rapidly progress during first-line therapy, and highlight the benefits of various therapeutic approaches to maximise individual patient outcomes.
- Debate the latest research which could further improve outcomes for patients with NSCLC.

Welcome message



Dear Colleagues,

Welcome to Geneva and thank you for attending this industry satellite symposium 'Choices across treatment lines: Maximising patient outcomes in advanced or metastatic NSCLC' at the European Lung Cancer Conference.

The aim of this symposium is to provide practical advice for clinicians treating advanced or metastatic NSCLC in an increasingly intricate therapy landscape. During this session, the expert Faculty will guide the delegates through case studies covering the harder-to-treat squamous NSCLC patient and the increasingly complex problem of what is the best approach for adenocarcinoma patients who rapidly progress. Throughout the case studies the audience will be asked to vote on which treatment options they would choose at defined points along the patients' therapeutic journey. This will allow the audience to compare their treatment choices with that of their peers, and provide an opportunity for the Faculty to discuss the potential gaps between current common practice and what the latest data suggests would be ideal.

We hope that you find this symposium engaging and informative, and that it will further your understanding of this evolving field, facilitating decision-making in your clinical practice. Accordingly, we aim to provide maximum interaction and discourse between the Faculty and the audience so that we may work together to optimise patient outcomes.

To continually improve our service to the clinical community, please provide your feedback on this symposium by completing the evaluation form provided with this booklet.

Yours faithfully,

Luis Paz-Ares

Luis Paz-Ares – Chair

Faculty biographies



Luis Paz-Ares

*Chair of the Medical Oncology Department,
Hospital Universitario Doce de Octubre, Madrid, Spain.*

Luis Paz-Ares graduated with a degree in Medicine from the Universidad Autonoma de Madrid in 1986, and completed a PhD in 1993 at the same University. He was a postdoctoral European Society for Medical Oncology (ESMO) Research Fellow in Medical Oncology at the Beatson Oncology Centre, University of Glasgow, Glasgow, Scotland (1993–1995), and completed a Master's degree in Clinical Pharmacology at the University of Glasgow in 1995. Dr Paz-Ares also completed a Master's degree in Clinical Unit Management at the UNED-Fundación Universidad Empresa, Madrid, Spain (2002–2003).

Between 2007-2014, he was Chair of the Medical Oncology Department at the Virgen del Rocío University Hospital in Seville, Spain. Dr Paz-Ares was then Head of the Pharmacology Unit and responsible for early clinical studies of thoracic and genitourinary tumours at the Hospital Universitario Doce de Octubre in Madrid, Spain (1995–1999; 2000–2007), and Visiting Research Fellow in the Prostate Cancer Programme at the Dana-Farber Cancer Institute in Boston, MA, USA (1999–2000).

Currently, Dr Paz-Ares is Chair of the Medical Oncology Department at the Hospital Universitario Doce de Octubre, Associate Professor at the Universidad Complutense, and Head of the Lung Cancer Unit at the CNIO (National Oncology Research Center), in Madrid, Spain.

Dr Paz-Ares's research focuses on lung cancer and strategies for new therapy development, both in the lab and from a clinical point of view, and he has published more than 240 papers in peer-reviewed journals, including *New England Journal of Medicine*, *Lancet*, *Lancet Oncology*, *Journal of Clinical Oncology* and many book chapters.

He is an active member of various scientific societies including American Society of Clinical Oncology (ASCO), ESMO, the International Association for the Study of Lung Cancer (IASLC) and collaborative groups, the European Organisation for Research and Treatment of Cancer (EORTC), the Spanish Lung Cancer Group and the International Germ Cell Cancer Collaborative Group.



Egbert Smit

Professor of Pulmonary Medicine

Netherlands Cancer Institute, Amsterdam, The Netherlands

Egbert Smit is Professor of Pulmonary Medicine, with an emphasis on Pulmonary Oncology, at the Netherlands Cancer Institute, Department of Thoracic Oncology in Amsterdam, The Netherlands.

After completing his PhD thesis involving multidisciplinary studies in medical oncology, genetics and pulmonary medicine in 1990, Professor Smit became a Board-Certified pulmonologist in 1997. Since 1986, he has been involved in research and clinical trials ranging from chemoprevention of lung cancer to the treatment of advanced non-small-cell lung cancer. He has been the principal investigator of several national and international phase II and III trials.

In recent years, Professor Smit has focused his research on translational oncology and molecular imaging. This has resulted in over 300 contributions to peer-reviewed journals and book publications, as well as participation in multiple online educational NSCLC resources.

Professor Smit is also active in several national and international societies such as the IASLC, ASCO, the American Association of Cancer Research (AACR) and the EORTC. He served as Chair of a multidisciplinary task force for the development of clinical guidelines in small-cell lung cancer in The Netherlands and has been a member of the European Society of Medical Oncology Lung and other thoracic tumours Faculty Group since 2011.

He is also on the review board of several leading oncology journals and has co-organised a number of national meetings on thoracic oncology and postgraduate teaching courses. Professor Smit has been involved as a promoter and co-reader for over 20 PhD students.



Benjamin Besse

*Head of the Thoracic Oncology Unit,
Institut Gustave Roussy, Villejuif, France.*

Benjamin Besse is Professor of Medical Oncology at Paris-Sud University, Orsay, France and a full-time Cancer Specialist at Gustave Roussy Cancer Campus, Villejuif, France. He gained his Medical Oncology degree in 2005 from Paris-Sud University and holds a PhD in Translational Research.

Currently, Dr Besse is Head of the Thoracic Oncology Unit at Gustave Roussy Cancer Campus. His main research interests are the application of molecular abnormalities to personalise treatment, circulating biomarkers, early drug development in thoracic tumours and thymic malignancies.

Dr Besse is involved in academic research through his position as member of the French Intergroupe Francophone de Cancérologie Thoracique (IFCT) Steering Committee and was elected Chair of the EORTC Lung Group in 2014. He coordinates the French network for thymic malignancies. He is Associate Editor of *European Respiratory Journal*. Dr Besse was Chair of the systemic treatment part of the European Society for Medical Oncology Consensus Conference on Lung Cancer published in *Annals of Oncology* in 2014. He has authored/co-authored more than 100 peer-reviewed papers.

Symposium information

Organisers

This educational activity has been planned and independently implemented by Springer Healthcare IME. Springer Healthcare IME is the Independent Medical Education group of Springer Healthcare, part of the Springer Nature global publishing group.

Further independent education resources in lung cancer, including an interactive case study and an on-demand webinar, can be found at www.ime.springerhealthcare.com/oncology

Filming and photography

Springer Healthcare IME may film or take photographs at the symposium that may be used for publicity and marketing materials. Your attendance at the meeting may mean you are featured in such photographs and films and, unless you notify a member of the Springer Healthcare IME team of your objection to this, your consent will be implied. member of the Springer Healthcare IME team of your objection to this your consent will be implied.

Post-event

To continually improve our service to the clinical community, please provide your feedback on this symposium by completing the evaluation form provided with this booklet.

Those who had their symposium badge scanned upon entry can expect to receive a scientific summary of this session by email within six weeks. If you did not have your badge scanned, please write your email address in the evaluation form to ensure you receive the scientific summary.

Educational sponsorship

This programme is made possible thanks to independent educational sponsorship from Eli Lilly and Company.



This independent programme is made possible thanks to educational sponsorship from Eli Lilly and Company